The EGFR-TKIs exhibit high-affinity binding to the mutated EGFR tyrosine kinase domain and have been used as an approach to treat advanced NSCLC in Japanese populations (Dagogo-Jack et al. 2018; Nogami et al. 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.